This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
What's in Store for Henry Schein (HSIC) in Q3 Earnings?
by Zacks Equity Research
Strengthening demand in the global dental and medical markets along with the recent investments are likely to have contributed to Henry Schein's (HSIC) Q3 performance.
Can Becton Dickinson (BDX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
SmileDirectClub (SDC) Introduces Two New Water Flossers
by Zacks Equity Research
SmileDirectClub (SDC) launched the new Large Tank and Compact Water Flossers, currently available at Shop.SmileDirectClub.com, Amazon, Walmart and Walmart.com.
Zacks.com featured highlights include: Becton, Dickinson and Co, Ternium and AutoNation
by Zacks Equity Research
Zacks.com featured highlights include: Becton, Dickinson and Co, Ternium and AutoNation
QIAGEN's (QGEN) New Manchester Facility to Fortify UK Foothold
by Zacks Equity Research
QIAGEN's (QGEN) new campus is expected to bring the benefits of transformational molecular diagnostics to Manchester and the global healthcare market.
3 Must-Buy Efficient Stocks to Boost Portfolio Returns
by Tirthankar Chakraborty
Becton, Dickinson and Company (BDX), Ternium (TX) & AutoNation (AN) are three must-buy efficient stocks that can enrich your portfolio now.
BDX or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BDX vs. MMSI: Which Stock Is the Better Value Option?
Teladoc (TDOC) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Robust customer uptake and novel innovations are likely to have contributed to growth for Teladoc (TDOC).
Intuitive Surgical (ISRG) Q3 Earnings Match Estimates, Up Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results reflect strong segmental performance.
The Zacks Analyst Blog Highlights: Oracle, Lowe's, Starbucks, Goldman Sachs and Becton, Dickinson and Co
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Lowe's, Starbucks, Goldman Sachs and Becton, Dickinson and Co
Top Stock Reports for Oracle, Lowe's & Starbucks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), Lowe's Companies, Inc. (LOW), and Starbucks Corporation (SBUX).
Here's Why You Should Invest In Henry Schein (HSIC) Now
by Zacks Equity Research
Investors continue to be optimistic about Henry Schein (HSIC) on its extensive global foothold and raised 2021 earnings guidance.
PerkinElmer (PKI) Receives EUA from FDA for Latest Assay
by Zacks Equity Research
PerkinElmer's (PKI) latest test receives EUA from the FDA, thereby enabling qualified laboratories to detect and differentiate SARS-CoV-2, influenza A, influenza B and RSV.
BD's (BDX) New Manufacturing Facility to Boost Supply Readiness
by Zacks Equity Research
BD's (BDX) latest manufacturing line is expected to not only boost supply capacity but also provide priority access to needles and syringes to the U.S. government.
BD's (BDX) Rotarex Atherectomy System Gets FDA 510 (k) Clearance
by Zacks Equity Research
BD's (BDX) Rotarex Atherectomy System receives expanded 510 (k) clearance from the FDA that can help in the treatment of in-stent restenosis in the United States.
Hologic (HOLX) Launches Novodiag System for On-Demand Testing
by Zacks Equity Research
Hologic (HOLX) introduces the Novodiag system in Europe for on-demand testing of infectious diseases and antimicrobial resistance.
Tesla, Becton, Dickinson and Co, Computer Programs and Systems, AutoNation and Paycom Software highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Tesla, Becton, Dickinson and Co, Computer Programs and Systems, AutoNation and Paycom Software highlighted as Zacks Bull and Bear of the Day
Bear Of The Day: Becton, Dickinson and Co (BDX)
by Brian Bolan
Despite a beating the number in the most recent report, this stock has fallen to the lowest Zacks Rank
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and regulatory approvals.
Here's Why You Should Add Omnicell (OMCL) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Omnicell (OMCL) on its strategic acquisitions and partnerships supporting each of the three legs of its strategy.
Cybersecurity Gains Prominence in MedTech: 3 Stocks to Focus on
by Debanjana Dey
Technology-based healthcare stocks like Henry Schein (HSIC), Veeva Systems (VEEV) and BD (BDX) are expected to continue their rally over the next few months.
BD's (BDX) Latest Diagnostic System to Improve Lab Efficiency
by Zacks Equity Research
BD's (BDX) new system is expected to address labs' needs for high-volume processing and increases in efficiency.
BD (BDX) Veritor At-Home COVID-19 Test Receives EUA From FDA
by Zacks Equity Research
EUA for BD's (BDX) At-Home COVID-19 test is expected to boost home testing to prevent outbreaks and limit the rise in COVID-19 cases from the Delta variant.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and regulatory approvals.
Here's Why You Should Add Omnicell (OMCL) to Your Portfolio
by Zacks Equity Research
Omnicell (OMCL) ended the second quarter with better-than-expected results, with the top line registering solid year-over-year growth.